Survodutide, a dual GLP-1/glucagon receptor agonist, shows promise for obesity and MASH treatment

Both Obesity and Metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of MASLD (fatty liver disease), are chronic metabolic diseases with significant health impacts. These conditions are closely linked, often co-occurring and driven by systemic metabolic dysfunction. Current management strategies include lifestyle modifications, bariatric surgery, and existing medications, but there remains a critical need for new, highly effective pharmacological interventions that can address the complex pathophysiology of both diseases, particularly for MASH where treatment options are limited.

This plain language review provides an overview of survodutide (BI 456906), a novel investigational medication. It synthesizes information from ongoing clinical trials evaluating survodutide's efficacy and safety in individuals living with obesity and MASH. The review describes the proposed mechanism of action for survodutide and summarizes the key health improvements and side effects observed in participants across these trials. General trial designs involve randomizing participants into groups receiving different doses of survodutide or a placebo, with primary endpoints focused on weight loss and improvements in liver health parameters.

Survodutide operates as a dual agonist for both the GLP-1R (glucagon-like peptide-1 receptor) and the glucagon receptor. This dual agonism is hypothesized to synergistically improve metabolic function, leading to significant benefits in conditions like obesity and MASH. The GLP-1R activation is well-known for its effects on satiety, glucose homeostasis, and weight reduction, while glucagon receptor agonism may contribute to energy expenditure and hepatic fat reduction. Clinical trials have indicated that survodutide helps people living with obesity achieve weight loss, and it is also being investigated for its potential to improve MASH by reducing abnormal fat accumulation in the liver. While specific quantitative results (e.g., exact percentages of weight loss or MASH resolution rates) are not detailed in this review, the overall findings suggest a favorable impact on metabolic parameters. Side effects experienced by participants in clinical trials are also described, consistent with other medications in this class, though specific adverse event rates are not provided here.

Survodutide's dual agonism at GLP-1R and glucagon receptor represents a promising multi-modal approach to address the complex metabolic dysregulation underlying obesity and MASH.